spironolactone has been researched along with Autoimmune Disease in 5 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 7.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| " We studied the effects of eplerenone, a novel aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy after autoimmune myocarditis." | 3.73 | Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. ( Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K, 2005) |
| "The spironolactone treatment did not block normal glucocorticoid receptor-mediated immune-suppression functions because mice receiving prednisolone, either with or without spironolactone, maintained normal body weights, hematocrits, and serum immune complexes." | 1.33 | Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear. ( Gross, ND; Kempton, JB; Trune, DR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wahed, MI | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Yamaguchi, K | 1 |
| Takahashi, T | 1 |
| Tachikawa, H | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Trune, DR | 1 |
| Kempton, JB | 1 |
| Gross, ND | 1 |
| Oosterhuis, HJ | 1 |
| Henriquet, F | 1 |
| Balestra, L | 1 |
| Prindull, G | 1 |
| Hotes, C | 1 |
| Meyer, HJ | 1 |
| Richtering, I | 1 |
5 other studies available for spironolactone and Autoimmune Disease
| Article | Year |
|---|---|
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship | 2005 |
Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear.
Topics: Aldosterone; Animals; Antigen-Antibody Complex; Auditory Threshold; Autoimmune Diseases; Body Weight | 2006 |
[On motor end-plate diseases with special reference to myasthenia gravis].
Topics: Acetylcholine; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Antigen-Antibody React | 1965 |
[On the therapy of myasthenia gravis. (Presentation of a case)].
Topics: Adrenocorticotropic Hormone; Adult; Autoantibodies; Autoimmune Diseases; Female; Humans; Myasthenia | 1970 |
[Treatment of an autoimmune disease of the eye with antilymphocyte serum combined with prednisolone, azathioprine, aldosterone and spironolactone].
Topics: Aldosterone; Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; Child; Humans; Immunosuppressi | 1970 |